Prevention of Malaria in Pregnancy:

WHO 2012 Policy
Recommendations for IPTp-SP
 (intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine)

•IPTp-SP should ideally be administered as directly observed therapy.

•Three tablets of SP (each tablet containing 500 mg/25 mg SP), giving the total required dosage of 1,500 mg/75 mg SP

•SP can be given with or without food.

•SP should not be administered to women receiving cotrimoxazole prophylaxis due to a higher risk of adverse events.

•The WHO recommends administration of 0.4 mg folic acid daily.

•This dose may be safely used in conjunction with SP.

Folic acid at a 5 mg or higher daily dose should not be given together with SP, as it counteracts SP’s efficacy as an antimalarial

•Pregnant women can receive SP at all scheduled ANC contacts:

•Starting at 13 weeks

•As long as doses are at least one month apart

•If the woman is not taking cotrimoxazole

•SP can be taken up to the time of delivery.

•Counsel pregnant women on importance of returning for repeat ANC contacts.

Finally a urine test for accurate tuberculosis detection

 

Scientists have finally developed a noninvasive tuberculosis test for a pool of people for whom such assessments have previously been difficult: people who don’t have HIV. The researchers’ test detects active tuberculosis infections from urine samples.

They say the technology has urgently needed and broad implications for screening, transmission control, and treatment management. Tuberculosis is one of the most common bacterial infections, with 9.6 million cases and 1.5 million deaths reported worldwide in 2014.

Previous attempts to develop urine tests for TB (ideal in low-resource settings because samples can be collected noninvasively and without specialized training) have only detected infections in HIV-positive patients, possibly because immune suppression leads to substantially elevated bacteria levels in the body. Seeking to capture small amounts of a sugar called LAM (which partially comprises the tuberculosis bacterium’s outer coat) in urine, Luisa Paris and colleagues screened 37 compounds to narrow in on a copper complex dye called RB221 that they embedded in tiny hydrogel meshes to form structures called nanocages.

The RB221 nanocages trapped LAM from urine, increasing detection sensitivity by 100- to 1,000 fold, all while excluding interfering compounds from the samples that could confound results. In 48 Peruvian HIV-negative tuberculosis patients who hadn’t yet been treated, the new test detected infections with greater than 95% sensitivity. What’s more, elevated LAM concentrations in urine correlated with increased amounts of bacteria and more severe disease (as measured by weight loss or a cough). The researchers also created nanocages to trap and detect other hallmarks of infection including very low abundance molecules named ESAT6 and CFP10. According to the authors, their next steps are to compare urinary LAM in patients before and after therapy to evaluate potential treatment-induced changes.